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Abstract
Parkinson’s Disease is one of the most common neurological disorders which disrupts the everyday lives of millions of people. This
disease is categorized by the loss of dopamine in the brain, specifically the Substantia Nigra. People diagnosed with PD suffer
from motor and cognitive impairments. While there is no one treatment which can completely cure the disease, there are many
treatments available which can help alleviate symptoms. However, most of the treatments cause many negative side effects.
Recently, a new physical therapy treatment, LSVT BIG has begun to show its effects. This revue describes the many factors and
treatments of Parkinson’s disease and explains the newly discovered treatment of LSVT BIG.
Introduction
Parkinson’s disease (PD) is a progressive neurological
disorder which disturbs one’s motor cortex, thereby
affecting one’s mobility. This disorder affects over one
million people in the United States alone and more than
ten million across the entire world (National Parkinson’s
Foundation, n.d.). Unfortunately, this disease slowly worsens from the time one is diagnosed. Even more, PD has
a large range of indications and effects. While many with
Parkinson’s disease have similar symptoms, no two individuals experience the illness in exactly the same way. If
you see someone shuffling down the street taking small
steps or shaking their hands quickly and repeatedly in
their lap, you can suspect that this person is suffering
from Parkinson’s Disease. What causes this neurological
disease, and what can we do to slow the progression and
treat the symptoms?
Methods
The information stated in the following paper was acquired through the Touro College Library, which grants
its students access to many useful databases such as
ProQuest, Ebsco, PubMed and others.
Pathophysiology
Patients with Parkinson’s Disease are lacking in dopamine, which is normally produced in the substantia nigra
part of the brain. The thalamus must have access to the
motor cortex in the brain, specifically to the basal ganglia,
in order to produce movement. Within the basal ganglia
there are two pathways which have opposite effects on
movement. The direct loop promotes movement, while
the indirect loop inhibits movement. In a healthy person,
the dopaminergic pathway maintains the balance between
the other two pathways, enabling the thalamus to have
control over the motor cortex and over the person’s
movements. This dopaminergic pathway works by exciting the direct pathway, while inhibiting the indirect pathway to promote movement. This happens in two ways.
First, the substantia nigra sends dopamine to the striatum which excites the striatum and causes it to inhibit
the globus pallidus. Thus, the globus pallidus is unable to

obstruct the thalamus. Second, the substantia nigra sends
dopamine directly to the globus pallidus, inhibiting it, so it
cannot prevent the thalamus from controlling the motor
cortex. In those with PD, much of the dopamine in the
substantia nigra is exhausted. Consequently, the globus
pallidus is excited and inhibits the thalamus. Thus, the
thalamus has little control over the motor cortex (Singh,
2018). See Figure 1.

Figure 1

Figure 1: GPi = Globus Pallidus internus, GPe = Globus
Pallidus externus, SNpr = Substantia Nigra, STN =
Subthalamic Nucleous, MC = Motor Cortex, PMC = Pre
Motor Cortex, SMA = Supplementary Motor Cortex
The arrows thickness represents the amount of increase
and decrease of neuronal actions. In the healthy person,
the arrows of the direct and indirect pathways which are
related to dopamine (explained above) are significantly
thicker than the arrows in the PD patient. Furthermore,
the Globus Pallidus internus has the power to inhibit the
thalamus in the PD patient as demonstrated by the thickness of the arrows (Singh, 2018).
The lack of dopamine causes akinesia, bradykinesia and
other motor deficits which are so commonly found in
patients with PD. As the levels of dopamine decrease, the
levels of Acetylcholine (Ach) increase. The increased Ach
is what causes the symptoms of tremors and rigidity in
PD patients. In other words, the loss of the dopaminergic
system leads to disinhibition of the cholinergic system
(Armstrong & Okun, 2020).
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Another major marker for Parkinson’s Disease is the
existence of the Lewy Body.The Lewy Body is a “neuronal
inclusion” which mainly contains a cluster of a-synuclein
proteins (Bridi & Hirth, 2018).
Causes of Parkinson Disease
PD is believed to be an idiopathic disease being that
scientists are unable to find one definitive cause of this
Parkinson’s disorder. However, there are factors that
increase one’s likelihood of developing Parkinson’s disease. First, there are those who have a genetic predisposition. The most established or proven genetic cause of
Parkinson’s is mutations in what is known as the Parkin
gene (Park2) (Shadrina, et al., 2007) or the PINK1 gene
(PARK6) as they both inhibit normal mitochondrial function (Seiraﬁ, et.al. 2015). Additionally, people who experience a head injury are at a greater risk for developing PD.
High milk and dairy intake and exposure to pesticides can
also increase one’s risk for developing PD. Interestingly,
research has found that there are certain steps one can
take in order to reduce his/her risk of developing the disease, such as cigarette smoking and consumption of coffee or other caffeinated drinks (Ascherio & Schwarzchild,
2016).
Symptoms of Parkinson’s Disease
PD is a progressive disorder, meaning there is no cure
and the disease slowly worsens over time. Most people
consider PD a disease which only affects movement, however this is not the case. Rather, Parkinson’s causes a large
range of symptoms and affects different systems in the
body. Individuals suffering from PD perceive the world
as much smaller than healthy individuals. Therefore, many
of the symptoms are correlated to this viewpoint. For
example, when a PD patient shuffles, one thinks that s/he
is walking normally. (Fox, et.al. 2011).
Motor Symptoms
There are two groups of symptoms caused by PD. First,
and more well recognized, are motor symptoms. Up
to 80% of dopamine in the Substantia Nigra is depleted before these motor symptoms become noticeable.
However, in order to be diagnosed with PD, people must
demonstrate some symptoms. First, they must exhibit
slow movement and low amplitude of everyday movements (shuffling of gait), otherwise known as bradykinesia.
Then, they must also display one additional cardinal sign
of Parkinson’s, which include rigidity, akinesia or unable to
initiate movement, lack of balance or tremors. As mentioned above, about 80% of PD patients suffer from limb
tremors, usually concerning the hand, which is caused by
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increased levels of Ach. Furthermore, several years after
initial symptoms, 25% -60% of patients with PD exhibit
frozen movements, while 40% – 80% of PD patients have
swallowing issues and 25% drool. Additionally, more than
50% suffer from speech impairments including quiet and
hurried speech (Sveinbjornsdottir, 2016). Additionally,
those with PD display a masked expression, also known
as bradykinesia of the face. This happens because when
a person is suffering from Parkinson’s Disease, all movements slow down including facial movements. The delay
of the facial muscles is what causes PD patients to lose
their ability to express themselves via facial expressions
(Bologna, et al., 2013).
Non-Motor Symptoms
Contrary to popular belief, Parkinson’s is not just a
movement disease, rather it affects non-motor abilities
as well. Even before the motor symptoms start and the
person is diagnosed, patients may experience a variety
of non-motor symptoms. These symptoms can be divided into three sections: autonomic function disturbances, sleep disturbances and neuropsychiatric symptoms
(Sveinbjornsdottir, 2016).
Autonomic Function Disturbances
Those with PD often experience rapid drops in blood
pressure causing dizziness, visual troubles and weakened cognition which can ultimately cause loss of
consciousness. Furthermore, the movement of the
gastrointestinal tract slows down. This can cause overstuffed feelings, gastric retention and constipation.
Constipation occurs in over 75% of PD patients. Also,
those with Parkinson’s suffer from an inability to control their urinary frequency and urgency. About 60%
of PD patients display frequent nocturia, needing to
wake up several times throughout the night to use the
bathroom (Sveinbjornsdottir, 2016).
Sleep Disturbances
Roughly two thirds of PD patients suffer from an assortment of sleep disorders. This can be due to physical or cognitive limitations of the disease itself, or due
to the different medications and treatments which are
being used to treat the patient’s symptoms. The most
common ailment is fractionated sleep. Studies show that
PD patients sleep lighter and have regular interruptions
throughout the night.This fractionated sleep can also be a
result of other PD sleep disorders such as frequent nocturia, difficulties with moving in bed and nocturnal tremors. Depression caused by Parkinson’s can also disturb a
patient’s sleep throughout the night. Additionally, about
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50% of people diagnosed with Parkinson’s undergo extreme daytime sleepiness. Some say that this is somewhat
caused by the dopaminergic drugs. Even more, 27-32%
of PD patients kick and smack while dreaming and others uncontrollably jerk while sleeping (Sveinbjornsdottir,
2016).
Neuropsychiatric Symptoms
Many with PD suffer from various Neuropsychiatric
Symptoms. The earliest indications consist of executive
functioning issues, visuospatial disfunction, weakened
speech fluency and memory loss. Additionally, in more
than a third of PD patients experience hallucinations
and illusions. Also, as the disease progresses some develop paranoia, particularly feeling suspicious towards
their spouse. Moreover, dementia is also common in
those with Parkinson’s. Other common Neuropsychiatric
symptoms include depression and anxiety. One third of
PD patients have clinically diagnosed depression and 17%
were confirmed to have a major depressive disorder
(Sveinbjornsdottir, 2016). All symptoms, whether they are
movement related or not, adversely affects the lives of
PD patients.
Unified Parkinson’s Disease Rating Scale
For any disease, when testing a new treatment, or tweaking a current treatment, there must be a way to measure
the success. Specifically for Parkinson’s disease, there are
different ways of measuring the severity of PD symptoms, thereby displaying the treatments progress. Most
frequently used is the Unified Parkinson’s Disease Rating
Scale (UPDRS). This rating tool is used to determine the
severity of the PD patient’s symptoms. It is divided into
four sections which evaluate the symptoms’ severity on
a 0-4 scale. First, UPDRS I measures non-motor daily behaviors such as sleep, mood and brain activity. Second,
UPDRS II assesses the patient’s motor abilities for daily
living, such as speech, chewing, handwriting, walking and
drooling. Third, UPDRS III is the section which includes
motor evaluation such as rigidity, gait and tremors. Last,
UPDRS IV calculates treatment complications such as
pain (Kleiner-Fisman, et.al. 2010).
Brief Overview of PD treatments
Although there is not a single cure for PD, there are
different treatments which target specific symptoms of
the disease. This includes both motor symptoms and
non-motor symptoms. Furthermore, there are three
types of treatments used to improve PD patient’s way of
life. There are medicinal treatments, surgical intervention
and physical therapies.

Drug Therapy
Many of the medicinal treatments for Parkinson’s Disease
patients target the dopaminergic pathway, working to
increase the dopamine in the patient’s brain. While
some medicines work better than others, no drug cures
symptoms completely. The most commonly used drug
is levodopa which increases the dopamine in the brain.
Primarily, levodopa targets the movement disorders of
PD. Although levodopa is still considered the most effective treatment, about 40% of patients develop motor
complications after 4-6 years of levodopa treatments.
There are other drugs taken to combat the side effects
of levodopa (Dong, et.al. 2016). Another commonly used
drug is amantadine. Many clinical trials have proved that
amantadine can lessen the dyskinesia side-effect of the
levodopa drug. It was also found to reduce the severity
of freezing gait. Thus, improving PD patients’ abilities to
perform daily activities. Additionally, there are less frequently used drugs such as anticholinergic drugs. These
drugs help by restoring the balance between dopamine
and acetylcholine. Anticholinergic drugs are mostly used
at the onset of the disease, when the primary symptom
is tremors. The use of this type of medication is very limited, as there are many side-effects which some believe
outweigh the benefits (Dong, et.al. 2016). Side-effects
include decreased cognitive function, especially in older
PD patients, constipation, blurred vision and tachycardia
(Lertxundi, et al., 2015).
Surgical Treatments
There are many surgical interventions which were proven to be beneficial for PD patients. One such method is
called Deep Brain Stimulation (DBS). This surgery places
electrodes at certain places in the brain which control
movements. They are either placed in the subthalamic
nucleus (STN), the globus pallidus interna (GPi), or the
ventralis intermedius (VIM) nucleus of the thalamus. DBS
improves patients’ movement abilities and may lessen
tremor severity. Yet, unlike other pharmaceutical drugs,
DBS has demonstrated little to no side-effects (Chou,
Grube, & Patil, 2012, p. 15). Another surgical treatment
is cell transplantation. This treatment has proven to be
effective on motor symptoms of PD. This works as the
transplanted stem cells can “infiltrate and integrate with
diseased tissue, differentiate into dopaminergic neurons
to replace damaged cells and reconstruct neuronal circuits to restore nerve function (Li, 2012).”
Physical Therapy
A major issue with medication for PD patients is that the
effectiveness of the medicinal drugs decreases over time.
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As a result, the creation of different exercises and physical
therapies have also proven to be an effective way of combating Parkinson’s disease. First, basic exercises lessen the
motor and even non-motor symptoms of those with PD.
Exercise increases mitochondrial respiration and arouses
neuroplasticity. Furthermore, recent clinical trials recommend aerobic exercises. They claim that these exercises
improve gait, physical performance and balance. They also
state that they impact fatigue, depression and improve
cognitive ability. Additionally, a Chinese exercise called
Tai Chi, through breathing exercises combined with slow
movements, has improved the balance of PD patients
(Dong, et.al. 2016). Finally, LSVT BIG, a relatively new approach to physical therapy in PD, has begun to show its
effectiveness.
What is LSVT BIG?
LSVT Big was created based on the success of a treatment called LSVT Loud. First introduced in 1995, LSVT
Loud was proven to be an effective way of improving the
strength and loudness of the voice of PD patients. LSVT
Loud is a treatment which focuses on how one feels and
sounds when talking loudly. Unlike many speech treatments which target many different speech systems, LSVT
Loud primarily focuses on increasing movement in the
respiratory and laryngeal systems. Currently, after conducting many studies and experiments, LSVT Loud was
proven to be a successful treatment (Fox, et.al. 2011).
After the success of LSVT-Loud, in 2005 LSVT-BIG was
first introduced (McDonnell, et al., 2017).
LSVT-BIG was created to combat the hypokinesia or
reduced amplitude movements which interfere with the
everyday lives of people with PD. The goal of the treatment is to revise the way the patient perceives movement
performance. LSVT BIG therapy includes four consecutive, one on one, 60-minute sessions per week in addition
to one (on treatment day) or two (non-treatment days)
15 to 20-minute home sessions per day.When performing
any action, patients are told to conduct large amplitude
movements. The beginning of each out-session includes
seven whole-body exercises such as reaching in more
than one direction, weight shifting and stepping. Next, the
patient works on five every-day movements, such as shifting positions, rolling over in bed and any others that the
patient requests to improve. Third, the patient practices
walking with larger amplitude, while standing straight. At
the end of the session, the patient works on more complicated tasks which are directly related to his/her goals and
abilities. Later in the treatment, this final segment would
increase in difficulty by either adding an additional task or
by enhancing the existing mission (Isaacson, et.al. 2018).
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Experiments Conducted
To prove the effectiveness of LSVT-BIG, there were numerous studies and experiments done on all different
types of people at all stages of Parkinson’s disease. One
such experiment performed, compared the results of 41
patients involved in general exercise to 43 patients participating in the LSVT-BIG program. After sixteen weeks,
they found the motor function of the LSVT-BIG patients
to have improved significantly more than the other 41
patients. Additionally, it was found that those participating
in the program increased their speed of moving. Another
study found that LSVT-BIG helped decrease response
time when prompted (McDonnell, et al., 2017).
Another study was done to see if LSVT-BIG also impacted the duration of a patient’s ‘off time,’ meaning the
time of day where one feels at his/her low. Eight patients
participated in the study. Before starting treatment, each
patient was required to report their ‘on’ and ‘off’ durations for three days. Then they were evaluated under the
UPDRS III scale on motor ability. Then they began treatment. The changes were measured every four weeks by
ministering different tests. The results proved that LSVTBIG therapy does lessen the duration of ‘off’ time as it
did significantly improves the UPDRS III scores (Ueno, et
al., 2017).
In addition, a non-controlled study was performed
which examined the effects that LSVT BIG had on eighteen PD patients. It was found that after just four weeks of
therapy, the participants experienced a 12-14% increase
in walking and walking rate (Fox, et.al. 2011).
A different blind study was done which took sixty people suffering from Parkinson’s disease and randomly assigned them to one of three therapies, LSVT BIG, Nordic
Walking in a group setting, or regular exercise with no
therapist. After four months of treatment, the average
improvement of the scores on the UPDRS III on patients
receiving LSVT BIG therapy was 5.05, while the scores of
those undergoing Nordic Walking or domestic training
worsened.This amount of scaled motor increase clinically
proves that LSVT BIG does improve the symptoms of PD
patients (Fox, et.al. 2011).
Another case study included twelve idiopathic PD patients who underwent LSVT BIG therapy treatment.There
were also two control groups: one with eight PD patients
who did not undergo any physical therapy and the other
included fourteen healthy individuals who experienced
the same experiment as the case study.The PD LSVT BIG
patients were given sixteen sessions, four sessions per
week for four weeks. Each session was an individualized
meeting with a licensed LSVT BIG therapist and lasted
one hour each morning. Each appointment began with
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using the patient’s entire body including “BIG” amplitude
exercises and “repetitive multidirectional movements.”
The second half of the meeting included daily activities
according to what the patient wished to focus on such as
buttoning shirts and putting on a coat.The results showed
the gait speed and the step length of patients undergoing
LSVT BIG increased. Furthermore, the LSVT BIG patients
displayed better functional mobility as they were able to
transition from sitting to standing faster and more often.
The LSVT BIG patients’ improvements were significantly
greater than the PD control group (Flood, et al., 2020).
Each of the experiments described above prove the
effectiveness of LSVT BIG therapy. There were countless
of other case studies conducted whose results were similar to the outcomes stated previously. Thus, it is safe to
conclude that LSVT BIG is an effective way of treating
Parkinson’s disease.
Conclusion
Parkinson’s Disease is a neurological disorder which affects tens of millions of people across the world. Primarily,
the disease is associated with progressive loss of dopamine in the brain. People with PD are affected in many
different areas of life including motor skills and cognitive
abilities. Unfortunately, researchers have not found one
perfect solution to completely cure Parkinson’s Disease.
Rather, there are only palliative solutions, treatments
which either ease the symptoms or slow the progression
of the disease however, doctors don’t often give patients
medication for two reasons. Often, many of the commonly used medicinal treatments can cause difficult side
effects. Secondly, as time progresses, the impact the medicine has on the body weakens as the patient becomes accustomed to the drug. Therefore, doctors and therapists
are beginning to use more non-invasive treatments such
as exercise and Physical Therapy. Recently, there has been
a new treatment, LSVT BIG, which targets the amplitude of the PD patients. This treatment has continuously
proved itself effective and worthwhile. Every Parkinson’s
patient should have the opportunity to undergo LSVT
BIG treatment.
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